45104
KNIGHT THERAPEUTICS INC.
Nov 22, 2022
Latin America and the Caribbean Region
Latin America and the Caribbean
Dec 17, 2022
B - Limited
Active
Approved : Jul 1, 2021
Signed : Jun 30, 2022
Invested : Dec 15, 2022
other
other
Regional Industry MAS LAC & EUR
Knight Therapeutics Inc. (Knight or the “company” - https://www.gud-knight.com) is a pan-American (ex-USA) specialty pharmaceutical company headquartered in Montreal, Canada that was founded in 2014 with the objective of acquiring or in-licensing innovative pharmaceutical products. In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America. Knight completed the 100% acquisition in August 2020. GBT owns manufacturing facilities for branded generic products in addition to a research and development center, all located in Argentina. With the GBT acquisition, Knight has expanded its operations in Latin America. The company is now directly present in 11 countries and has distributors in Central America and the Caribbean.
The proposed IFC investment will be used to partially provide financing in connection with the acquisition of the rights to manufacture, market and sell Exelon® in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”), as well as its commercialization in Canada and Latin America. Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.
Given travel restrictions related to the COVID-19 pandemic, IFC’s review of this investment was conducted in a virtual format and consisted of meetings with the Knight Management Team. The company presented an overview of its operations, the strategy to manufacture, sell and distribute Exelon®, HR procedures, management of contractors and suppliers, and disposal of expired or non-conforming products.
The due diligence was focused on Knight’s activities associated with the marketing and distribution of products, (including Exelon®) and did not cover other any of GBT’s existing manufacturing facilities in Argentina. The virtual appraisal was conducted in May 20212021 and the ESRS was last updated in November 2022 based on subsequent communications with the company.